[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CA1000631A - Rapamycin from streptomyces hygroscopicus nrrl 5491 - Google Patents

Rapamycin from streptomyces hygroscopicus nrrl 5491

Info

Publication number
CA1000631A
CA1000631A CA181,648A CA181648A CA1000631A CA 1000631 A CA1000631 A CA 1000631A CA 181648 A CA181648 A CA 181648A CA 1000631 A CA1000631 A CA 1000631A
Authority
CA
Canada
Prior art keywords
rapamycin
streptomyces hygroscopicus
hygroscopicus nrrl
nrrl
streptomyces
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CA181,648A
Other languages
English (en)
Other versions
CA181648S (en
Inventor
Surendra N. Sehgal
Claude Vezina
Teodora M. Blazekovic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth Canada Inc
Original Assignee
Ayerst Mckenna and Harrison Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ayerst Mckenna and Harrison Inc filed Critical Ayerst Mckenna and Harrison Inc
Application granted granted Critical
Publication of CA1000631A publication Critical patent/CA1000631A/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C12P17/188—Heterocyclic compound containing in the condensed system at least one hetero ring having nitrogen atoms and oxygen atoms as the only ring heteroatoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/886—Streptomyces
    • Y10S435/898—Streptomyces hygroscopicus

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Compounds Of Unknown Constitution (AREA)
CA181,648A 1972-09-29 1973-09-21 Rapamycin from streptomyces hygroscopicus nrrl 5491 Expired CA1000631A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29369972A 1972-09-29 1972-09-29

Publications (1)

Publication Number Publication Date
CA1000631A true CA1000631A (en) 1976-11-30

Family

ID=23130177

Family Applications (1)

Application Number Title Priority Date Filing Date
CA181,648A Expired CA1000631A (en) 1972-09-29 1973-09-21 Rapamycin from streptomyces hygroscopicus nrrl 5491

Country Status (21)

Country Link
US (1) US3929992A (nl)
AR (1) AR197832A1 (nl)
AU (1) AU474405B2 (nl)
BE (1) BE805505A (nl)
CA (1) CA1000631A (nl)
CH (1) CH591558A5 (nl)
CS (1) CS185630B2 (nl)
DD (1) DD107070A5 (nl)
DE (1) DE2347682C2 (nl)
DK (1) DK134607B (nl)
ES (1) ES419160A1 (nl)
FR (1) FR2201076B1 (nl)
GB (1) GB1436447A (nl)
HK (1) HK51079A (nl)
HU (1) HU166346B (nl)
IE (1) IE38267B1 (nl)
IN (1) IN139114B (nl)
NL (1) NL175641C (nl)
SE (1) SE399437B (nl)
YU (1) YU37358B (nl)
ZA (1) ZA737247B (nl)

Families Citing this family (392)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4069316A (en) * 1976-11-01 1978-01-17 Takeda Chemical Industries, Ltd. Method for producing antibiotic T-42082 and antibiotic T-42082
US5206018A (en) * 1978-11-03 1993-04-27 Ayerst, Mckenna & Harrison, Inc. Use of rapamycin in treatment of tumors
US5066493A (en) * 1978-11-03 1991-11-19 American Home Products Corporation Rapamycin in treatment of tumors
US4230692A (en) * 1978-11-03 1980-10-28 Ayerst Mckenna & Harrison, Inc. Ravidomycin and process of preparation
AU543727B2 (en) 1980-06-02 1985-05-02 Ayerst Mckenna & Harrison Inc. Injectable composition of rapamycin
US4316885A (en) 1980-08-25 1982-02-23 Ayerst, Mckenna And Harrison, Inc. Acyl derivatives of rapamycin
US4401653A (en) * 1981-03-09 1983-08-30 Ayerst, Mckenna & Harrison Inc. Combination of rapamycin and picibanil for the treatment of tumors
US4375464A (en) * 1981-11-19 1983-03-01 Ayerst, Mckenna & Harrison Inc. Antibiotic AY24,668 and process of preparation
AR240943A1 (es) * 1985-02-05 1991-03-27 Sankio Company Limited Nuevo compuesto agroquimico denominado "sustancia n*51262" procedimiento para prepararlo y composicion que lo comprende"
US5100899A (en) * 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
US5120726A (en) * 1991-03-08 1992-06-09 American Home Products Corporation Rapamycin hydrazones
US5023264A (en) * 1990-07-16 1991-06-11 American Home Products Corporation Rapamycin oximes
US5023263A (en) * 1990-08-09 1991-06-11 American Home Products Corporation 42-oxorapamycin
US5023262A (en) * 1990-08-14 1991-06-11 American Home Products Corporation Hydrogenated rapamycin derivatives
US5378696A (en) * 1990-09-19 1995-01-03 American Home Products Corporation Rapamycin esters
US5358944A (en) * 1990-09-19 1994-10-25 American Home Products Corporation Rapamycin esters for treating transplantation rejection
US5221670A (en) * 1990-09-19 1993-06-22 American Home Products Corporation Rapamycin esters
US5130307A (en) * 1990-09-28 1992-07-14 American Home Products Corporation Aminoesters of rapamycin
US5233036A (en) * 1990-10-16 1993-08-03 American Home Products Corporation Rapamycin alkoxyesters
US5078999A (en) 1991-02-22 1992-01-07 American Home Products Corporation Method of treating systemic lupus erythematosus
US5080899A (en) * 1991-02-22 1992-01-14 American Home Products Corporation Method of treating pulmonary inflammation
US5120842A (en) * 1991-04-01 1992-06-09 American Home Products Corporation Silyl ethers of rapamycin
US5321009A (en) * 1991-04-03 1994-06-14 American Home Products Corporation Method of treating diabetes
US5100883A (en) * 1991-04-08 1992-03-31 American Home Products Corporation Fluorinated esters of rapamycin
US5118678A (en) * 1991-04-17 1992-06-02 American Home Products Corporation Carbamates of rapamycin
US5147877A (en) * 1991-04-18 1992-09-15 Merck & Co. Inc. Semi-synthetic immunosuppressive macrolides
US5091389A (en) * 1991-04-23 1992-02-25 Merck & Co., Inc. Lipophilic macrolide useful as an immunosuppressant
US5138051A (en) * 1991-08-07 1992-08-11 American Home Products Corporation Rapamycin analogs as immunosuppressants and antifungals
US5102876A (en) * 1991-05-07 1992-04-07 American Home Products Corporation Reduction products of rapamycin
US5776943A (en) * 1991-05-14 1998-07-07 American Home Products Corporation Rapamycin metabolites
US5118677A (en) * 1991-05-20 1992-06-02 American Home Products Corporation Amide esters of rapamycin
US5120727A (en) * 1991-05-29 1992-06-09 American Home Products Corporation Rapamycin dimers
US5120725A (en) * 1991-05-29 1992-06-09 American Home Products Corporation Bicyclic rapamycins
SG43072A1 (en) 1991-06-18 1997-10-17 American Home Prod Method of treating adult t-cell leukemia/lymphoma
IL102414A (en) * 1991-07-25 1996-08-04 Univ Louisville Res Found Medicinal preparations for the treatment of ocular inflammation, containing rapamycin
US5162333A (en) * 1991-09-11 1992-11-10 American Home Products Corporation Aminodiesters of rapamycin
US5286730A (en) * 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory disease
US5286731A (en) * 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory bowel disease
US5151413A (en) * 1991-11-06 1992-09-29 American Home Products Corporation Rapamycin acetals as immunosuppressant and antifungal agents
US5164399A (en) * 1991-11-18 1992-11-17 American Home Products Corporation Rapamycin pyrazoles
US5516781A (en) * 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
US5221740A (en) * 1992-01-16 1993-06-22 American Home Products Corporation Oxepane isomers of rapamycin useful as immunosuppressive agents
US5262424A (en) * 1992-02-18 1993-11-16 American Home Products Corporation Composition of sulfonylcarbamates of rapamycin and method of treating diseases requiring immunosuppression therewith
US5177203A (en) * 1992-03-05 1993-01-05 American Home Products Corporation Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents
DE69302945T2 (de) 1992-03-27 1996-10-10 American Home Prod 29-Demethoxyrapamycin zur Induktion der Immunosuppression
JPH07505628A (ja) * 1992-03-30 1995-06-22 アメリカン・ホーム・プロダクツ・コーポレイション 静脈注射用のラパマイシン製剤
US5288711A (en) * 1992-04-28 1994-02-22 American Home Products Corporation Method of treating hyperproliferative vascular disease
US5256790A (en) * 1992-08-13 1993-10-26 American Home Products Corporation 27-hydroxyrapamycin and derivatives thereof
CA2106034A1 (en) * 1992-09-24 1994-03-25 Ralph J. Russo 21-norrapamycin
US5318895A (en) * 1992-10-05 1994-06-07 Merck & Co., Inc. Aspergillus niger mutants
US5489680A (en) * 1992-10-13 1996-02-06 American Home Products Corporation Carbamates of rapamycin
US5302584A (en) * 1992-10-13 1994-04-12 American Home Products Corporation Carbamates of rapamycin
US5434260A (en) * 1992-10-13 1995-07-18 American Home Products Corporation Carbamates of rapamycin
US5480989A (en) * 1992-10-13 1996-01-02 American Home Products Corporation Carbamates of rapamycin
US5480988A (en) * 1992-10-13 1996-01-02 American Home Products Corporation Carbamates of rapamycin
US5262423A (en) * 1992-10-29 1993-11-16 American Home Products Corporation Rapamycin arylcarbonyl and alkoxycarbonyl carbamates as immunosuppressive and antifungal agents
US5258389A (en) * 1992-11-09 1993-11-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
US5260300A (en) * 1992-11-19 1993-11-09 American Home Products Corporation Rapamycin carbonate esters as immuno-suppressant agents
US5482945A (en) * 1992-12-22 1996-01-09 American Home Products Corporation Innovative technique for immunosuppression involving administration of rapamycin loaded formed blood elements
US5349060A (en) * 1993-01-07 1994-09-20 American Home Products Corporation Rapamycin 31-ester with N,N-dimethylglycine derivatives useful as immunosuppressive agents
GB9302569D0 (en) * 1993-02-10 1993-03-24 Smithkline Beecham Plc Novel compound
US5252579A (en) * 1993-02-16 1993-10-12 American Home Products Corporation Macrocyclic immunomodulators
US5310903A (en) * 1993-03-05 1994-05-10 Merck & Co., Inc. Imidazolidyl rapamycin derivatives
US5310901A (en) * 1993-03-05 1994-05-10 Merck & Co., Inc. O-heteroaryl, O-alkylheteroaryl, O-alkenylheteroaryl and O-alkynlheteroarylrapamycin derivatives
US7279561B1 (en) 1993-04-23 2007-10-09 Wyeth Anti-rapamycin monoclonal antibodies
JPH08509499A (ja) 1993-04-23 1996-10-08 アボツト・ラボラトリーズ ラパマイシン結合体及び抗体
US5504091A (en) * 1993-04-23 1996-04-02 American Home Products Corporation Biotin esters of rapamycin
AT408520B (de) * 1993-05-27 2001-12-27 Novartis Erfind Verwalt Gmbh Galenische formulierungen
CH686761A5 (de) * 1993-05-27 1996-06-28 Sandoz Ag Galenische Formulierungen.
GB9315914D0 (en) * 1993-07-31 1993-09-15 Smithkline Beecham Plc Novel compound
US5387680A (en) * 1993-08-10 1995-02-07 American Home Products Corporation C-22 ring stabilized rapamycin derivatives
US5516770A (en) * 1993-09-30 1996-05-14 American Home Products Corporation Rapamycin formulation for IV injection
IL111004A (en) * 1993-09-30 1998-06-15 American Home Prod Oral formulations of rapamycin
US5536729A (en) * 1993-09-30 1996-07-16 American Home Products Corporation Rapamycin formulations for oral administration
US5616588A (en) * 1993-09-30 1997-04-01 American Home Products Corporation Rapamycin formulation for IV injection
US5373014A (en) * 1993-10-08 1994-12-13 American Home Products Corporation Rapamycin oximes
US5378836A (en) * 1993-10-08 1995-01-03 American Home Products Corporation Rapamycin oximes and hydrazones
US5391730A (en) * 1993-10-08 1995-02-21 American Home Products Corporation Phosphorylcarbamates of rapamycin and oxime derivatives thereof
US5527907A (en) * 1993-11-19 1996-06-18 Abbott Laboratories Macrolide immunomodulators
CA2175215C (en) * 1993-11-19 2008-06-03 Yat Sun Or Semisynthetic analogs of rapamycin (macrolides) being immunomodulators
US5385908A (en) * 1993-11-22 1995-01-31 American Home Products Corporation Hindered esters of rapamycin
US5385910A (en) * 1993-11-22 1995-01-31 American Home Products Corporation Gem-distributed esters of rapamycin
US5385909A (en) * 1993-11-22 1995-01-31 American Home Products Corporation Heterocyclic esters of rapamycin
US5389639A (en) * 1993-12-29 1995-02-14 American Home Products Company Amino alkanoic esters of rapamycin
US5525610A (en) * 1994-03-31 1996-06-11 American Home Products Corporation 42-Epi-rapamycin and pharmaceutical compositions thereof
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US6150137A (en) * 1994-05-27 2000-11-21 Ariad Pharmaceuticals, Inc. Immunosuppressant target proteins
US5463048A (en) * 1994-06-14 1995-10-31 American Home Products Corporation Rapamycin amidino carbamates
WO1996006847A1 (en) * 1994-08-31 1996-03-07 Pfizer Inc. Process for preparing demethylrapamycins
PE52896A1 (es) 1994-10-26 1996-12-12 Novartis Ag Composicion farmaceutica
US5491231A (en) * 1994-11-28 1996-02-13 American Home Products Corporation Hindered N-oxide esters of rapamycin
US5563145A (en) * 1994-12-07 1996-10-08 American Home Products Corporation Rapamycin 42-oximes and hydroxylamines
US5561138A (en) * 1994-12-13 1996-10-01 American Home Products Corporation Method of treating anemia
US5606222A (en) * 1994-12-29 1997-02-25 Philips Electronics North America Corporation Lighting system with a device for reducing system wattage
US5496832A (en) * 1995-03-09 1996-03-05 American Home Products Corporation Method of treating cardiac inflammatory disease
BE1009856A5 (fr) * 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
US5780462A (en) * 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
US5922730A (en) * 1996-09-09 1999-07-13 American Home Products Corporation Alkylated rapamycin derivatives
US7282220B1 (en) 1996-11-05 2007-10-16 Hsing-Wen Sung Genipin-crosslinked gelatin microspheres as drug carrier
US5989591A (en) * 1997-03-14 1999-11-23 American Home Products Corporation Rapamycin formulations for oral administration
US6273913B1 (en) 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
US5985325A (en) * 1997-06-13 1999-11-16 American Home Products Corporation Rapamycin formulations for oral administration
US6890546B2 (en) 1998-09-24 2005-05-10 Abbott Laboratories Medical devices containing rapamycin analogs
US6015815A (en) 1997-09-26 2000-01-18 Abbott Laboratories Tetrazole-containing rapamycin analogs with shortened half-lives
US20060198867A1 (en) * 1997-09-25 2006-09-07 Abbott Laboratories, Inc. Compositions and methods of administering rapamycin analogs using medical devices for long-term efficacy
US20030129215A1 (en) * 1998-09-24 2003-07-10 T-Ram, Inc. Medical devices containing rapamycin analogs
US7399480B2 (en) * 1997-09-26 2008-07-15 Abbott Laboratories Methods of administering tetrazole-containing rapamycin analogs with other therapeutic substances using medical devices
US8257725B2 (en) * 1997-09-26 2012-09-04 Abbott Laboratories Delivery of highly lipophilic agents via medical devices
US7357942B2 (en) * 1997-09-26 2008-04-15 Abbott Laboratories Compositions, systems, and kits for administering zotarolimus and paclitaxel to blood vessel lumens
US8257726B2 (en) * 1997-09-26 2012-09-04 Abbott Laboratories Compositions, systems, kits, and methods of administering rapamycin analogs with paclitaxel using medical devices
US7378105B2 (en) * 1997-09-26 2008-05-27 Abbott Laboratories Drug delivery systems, kits, and methods for administering zotarolimus and paclitaxel to blood vessel lumens
US8057816B2 (en) * 1997-09-26 2011-11-15 Abbott Laboratories Compositions and methods of administering paclitaxel with other drugs using medical devices
US8394398B2 (en) * 1997-09-26 2013-03-12 Abbott Laboratories Methods of administering rapamycin analogs with anti-inflammatories using medical devices
SK5732000A3 (en) * 1997-10-22 2000-10-09 Ponikau Jens The use of an antifungal agent to reduce or eliminate non-invasive fungus induced rhinosinusitis, a pharmaceutical compostion, an antifungal formulation and industrial product comprising the same
US20030216303A1 (en) * 1998-03-06 2003-11-20 Michael Ambuhl Emulsion preconcentrates containing cyclosporin or a macrolide
US6015809A (en) * 1998-08-17 2000-01-18 American Home Products Corporation Photocyclized rapamycin
US7455853B2 (en) * 1998-09-24 2008-11-25 Abbott Cardiovascular Systems Inc. Medical devices containing rapamycin analogs
US8257724B2 (en) * 1998-09-24 2012-09-04 Abbott Laboratories Delivery of highly lipophilic agents via medical devices
US20060240070A1 (en) * 1998-09-24 2006-10-26 Cromack Keith R Delivery of highly lipophilic agents via medical devices
US7960405B2 (en) * 1998-09-24 2011-06-14 Abbott Laboratories Compounds and methods for treatment and prevention of diseases
GB9826882D0 (en) 1998-12-07 1999-01-27 Novartis Ag Organic compounds
US6331547B1 (en) 1999-08-18 2001-12-18 American Home Products Corporation Water soluble SDZ RAD esters
US7807211B2 (en) 1999-09-03 2010-10-05 Advanced Cardiovascular Systems, Inc. Thermal treatment of an implantable medical device
US6790228B2 (en) * 1999-12-23 2004-09-14 Advanced Cardiovascular Systems, Inc. Coating for implantable devices and a method of forming the same
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
GB0008785D0 (en) 2000-04-10 2000-05-31 Novartis Ag Organic compounds
US6573074B2 (en) * 2000-04-12 2003-06-03 Smithkline Beecham Plc Methods for ansamitocin production
US8236048B2 (en) 2000-05-12 2012-08-07 Cordis Corporation Drug/drug delivery systems for the prevention and treatment of vascular disease
US7419678B2 (en) * 2000-05-12 2008-09-02 Cordis Corporation Coated medical devices for the prevention and treatment of vascular disease
US7300662B2 (en) 2000-05-12 2007-11-27 Cordis Corporation Drug/drug delivery systems for the prevention and treatment of vascular disease
US6670355B2 (en) * 2000-06-16 2003-12-30 Wyeth Method of treating cardiovascular disease
JP2004509898A (ja) 2000-09-19 2004-04-02 ワイス 水溶性ラパマイシンエステル
US6399625B1 (en) 2000-09-27 2002-06-04 Wyeth 1-oxorapamycins
US20060222756A1 (en) * 2000-09-29 2006-10-05 Cordis Corporation Medical devices, drug coatings and methods of maintaining the drug coatings thereon
MXPA03002871A (es) 2000-09-29 2004-12-06 Johnson & Johnson Dispositivos medicos recubiertos.
US7261735B2 (en) * 2001-05-07 2007-08-28 Cordis Corporation Local drug delivery devices and methods for maintaining the drug coatings thereon
US6399626B1 (en) 2000-10-02 2002-06-04 Wyeth Hydroxyesters of 7-desmethylrapamycin
US6440991B1 (en) 2000-10-02 2002-08-27 Wyeth Ethers of 7-desmethlrapamycin
TWI286074B (en) 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
TWI233359B (en) * 2001-04-06 2005-06-01 Wyeth Corp Pharmaceutical composition for treating neoplasm
TWI296196B (en) * 2001-04-06 2008-05-01 Wyeth Corp Antineoplastic combinations
US8182527B2 (en) 2001-05-07 2012-05-22 Cordis Corporation Heparin barrier coating for controlled drug release
US20020198137A1 (en) * 2001-06-01 2002-12-26 Wyeth Antineoplastic combinations
UA77200C2 (en) 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
ES2246409T3 (es) 2001-08-22 2006-02-16 Wyeth 29-enoles de rapamicina.
US6680330B2 (en) 2001-08-22 2004-01-20 Wyeth Rapamycin dialdehydes
US20080145402A1 (en) * 2001-09-10 2008-06-19 Abbott Cardiovascular Systems Inc. Medical Devices Containing Rapamycin Analogs
US7195640B2 (en) 2001-09-25 2007-03-27 Cordis Corporation Coated medical devices for the treatment of vulnerable plaque
US20030065377A1 (en) 2001-09-28 2003-04-03 Davila Luis A. Coated medical devices
US7682387B2 (en) 2002-04-24 2010-03-23 Biosensors International Group, Ltd. Drug-delivery endovascular stent and method for treating restenosis
US6939376B2 (en) * 2001-11-05 2005-09-06 Sun Biomedical, Ltd. Drug-delivery endovascular stent and method for treating restenosis
CN1615137A (zh) * 2002-01-10 2005-05-11 诺瓦提斯公司 用于预防和治疗血管疾病、包含雷帕霉素及其衍生物的药物递送系统
US20040024450A1 (en) * 2002-04-24 2004-02-05 Sun Biomedical, Ltd. Drug-delivery endovascular stent and method for treating restenosis
US20030204168A1 (en) * 2002-04-30 2003-10-30 Gjalt Bosma Coated vascular devices
US20070083258A1 (en) 2005-10-06 2007-04-12 Robert Falotico Intraluminal device and therapeutic agent combination for treating aneurysmal disease
CN100569944C (zh) 2002-07-16 2009-12-16 百奥帝卡技术有限公司 聚酮化合物和其它天然产物的产生
PT1553940E (pt) 2002-07-30 2008-05-09 Wyeth Corp Formulações parentéricas contendo um hidroxi-éster de rapamicina
NZ538568A (en) * 2002-09-06 2010-09-30 Abbott Lab Medical device having hydration inhibitor
WO2004022767A1 (en) * 2002-09-09 2004-03-18 Biocon Limited Solid state fermentation and fed batch for the production of an immunosuppressant
KR20050084559A (ko) * 2002-09-17 2005-08-26 와이어쓰 경구 제형
US6919100B2 (en) * 2003-01-22 2005-07-19 Cordis Corporation Method for coating medical devices
US20050038504A1 (en) 2003-01-22 2005-02-17 Harry Halleriet Kit for applying drug coating to a medical device in surgeon room
US8318235B2 (en) * 2003-01-22 2012-11-27 Cordis Corporation Method for applying drug coating to a medical device in surgeon room
AR042938A1 (es) * 2003-02-06 2005-07-06 Wyeth Corp Uso del cci-779 en el tratamiento de la fibrosis hepatica
US20040167572A1 (en) 2003-02-20 2004-08-26 Roth Noah M. Coated medical devices
UA83484C2 (uk) * 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
US7527632B2 (en) * 2003-03-31 2009-05-05 Cordis Corporation Modified delivery device for coated medical devices
KR20060006058A (ko) * 2003-04-22 2006-01-18 와이어쓰 항신생물성 배합물
US20050008640A1 (en) * 2003-04-23 2005-01-13 Wendy Waegell Method of treating transplant rejection
US7160867B2 (en) 2003-05-16 2007-01-09 Isotechnika, Inc. Rapamycin carbohydrate derivatives
US20040236416A1 (en) * 2003-05-20 2004-11-25 Robert Falotico Increased biocompatibility of implantable medical devices
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
US20050033417A1 (en) * 2003-07-31 2005-02-10 John Borges Coating for controlled release of a therapeutic agent
US20050137677A1 (en) 2003-12-17 2005-06-23 Rush Scott L. Endovascular graft with differentiable porosity along its length
US20050249776A1 (en) * 2003-12-19 2005-11-10 Chen Chao C Coated aneurysmal repair device
US8747881B2 (en) 2003-12-19 2014-06-10 Cordis Corporation Intraluminal medical devices in combination with therapeutic agents
US8652502B2 (en) * 2003-12-19 2014-02-18 Cordis Corporation Local vascular delivery of trichostatin A alone or in combination with sirolimus to prevent restenosis following vascular injury
PT1701698E (pt) * 2004-01-08 2008-03-27 Wyeth Corp Composição farmacêutica para a administração oral de cci-779
US7303758B2 (en) * 2004-01-20 2007-12-04 Cordis Corporation Local vascular delivery of mycophenolic acid in combination with rapamycin to prevent restenosis following vascular injury
US7806924B2 (en) * 2004-02-18 2010-10-05 Cordis Corporation Implantable structures for local vascular delivery of cladribine in combination with rapamycin for restenosis
US20050187608A1 (en) * 2004-02-24 2005-08-25 O'hara Michael D. Radioprotective compound coating for medical devices
EP1568394A1 (en) 2004-02-26 2005-08-31 Muijs van de Moer, Wouter Matthijs Coated electrode
US8828416B2 (en) 2004-03-09 2014-09-09 Cordis Corporation Local vascular delivery of topotecan in combination with rapamycin to prevent restenosis following vascular injury
US8431145B2 (en) 2004-03-19 2013-04-30 Abbott Laboratories Multiple drug delivery from a balloon and a prosthesis
EP1735042B1 (en) * 2004-03-19 2011-11-23 Abbott Laboratories Multiple drug delivery from a balloon and a prosthesis
US7875282B2 (en) * 2004-03-22 2011-01-25 Cordis Corporation Coated medical device for local vascular delivery of Panzem® in combination with rapamycin to prevent restenosis following vascular injury
US7695731B2 (en) 2004-03-22 2010-04-13 Cordis Corporation Local vascular delivery of etoposide in combination with rapamycin to prevent restenosis following vascular injury
US8003122B2 (en) 2004-03-31 2011-08-23 Cordis Corporation Device for local and/or regional delivery employing liquid formulations of therapeutic agents
US7989490B2 (en) * 2004-06-02 2011-08-02 Cordis Corporation Injectable formulations of taxanes for cad treatment
US7846940B2 (en) * 2004-03-31 2010-12-07 Cordis Corporation Solution formulations of sirolimus and its analogs for CAD treatment
CA2562805C (en) * 2004-04-12 2014-03-11 Biocon Limited Process for the production of macrolides using a novel strain, streptomyces sp. bicc 7522
AU2005238431A1 (en) 2004-04-14 2005-11-10 Wyeth Regiospecific synthesis of rapamycin 42-ester derivatives
MXPA06011883A (es) 2004-04-14 2006-12-14 Wyeth Corp 42-ester de prolina-rapamicina con acido 2,2-bis(hidroximetil)propionico y sintesis enzimatica de dos etapas de 42-ester de prolina-rapamicina con acido 2,2-bis(hidroximetil)propionico y 42-ester de rapamicina con acido 2,2-bis(hidroximetil)propionic
CN1942478A (zh) * 2004-04-14 2007-04-04 惠氏公司 用于制备与二羧酸的纳巴霉素42－酯和fk－506 32－酯的方法，用于纳巴霉素配合物的前体和抗体
US8007737B2 (en) 2004-04-14 2011-08-30 Wyeth Use of antioxidants to prevent oxidation and reduce drug degradation in drug eluting medical devices
US20050232965A1 (en) * 2004-04-15 2005-10-20 Robert Falotico Local administration of a combination of rapamycin and 17 beta-estradiol for the treatment of vulnerable plaque
BRPI0510277A (pt) * 2004-04-27 2007-10-30 Wyeth Corp método para marcar especificamente uma rapamicina, rapamicina especificamente marcada, composição, e, kit
GB0417852D0 (en) 2004-08-11 2004-09-15 Biotica Tech Ltd Production of polyketides and other natural products
AR050374A1 (es) * 2004-08-20 2006-10-18 Wyeth Corp Forma polimorfica de rafampicina
EP1781672B1 (en) * 2004-08-27 2010-10-06 Cordis Corporation Solvent free amorphous rapamycin
WO2006031664A1 (en) * 2004-09-10 2006-03-23 Ivax Pharmaceuticals S.R.O. Process for isolation of crystalline tacrolimus
CN101031653A (zh) * 2004-09-10 2007-09-05 伊瓦克斯制药有限公司 大环内酯化合物的分离方法
WO2006029726A1 (en) * 2004-09-16 2006-03-23 Bayer Healthcare Ag Dermally applicable formulations for treating skin diseases in animals
US7901451B2 (en) 2004-09-24 2011-03-08 Biosensors International Group, Ltd. Drug-delivery endovascular stent and method for treating restenosis
US20060094744A1 (en) * 2004-09-29 2006-05-04 Maryanoff Cynthia A Pharmaceutical dosage forms of stable amorphous rapamycin like compounds
US20060129225A1 (en) * 2004-12-15 2006-06-15 Kopia Gregory A Device for the delivery of a cardioprotective agent to ischemic reperfused myocardium
GB0503936D0 (en) 2005-02-25 2005-04-06 San Raffaele Centro Fond Method
US20100061994A1 (en) * 2005-03-11 2010-03-11 Rose Mary Sheridan Medical uses of 39-desmethoxyrapamycin and analogues thereof
GB0504994D0 (en) 2005-03-11 2005-04-20 Biotica Tech Ltd Novel compounds
WO2007032777A2 (en) 2005-03-23 2007-03-22 Abbott Laboratories Compositions and methods of administering rapamycin analogs using medical devices for long-term efficacy
WO2006102359A2 (en) * 2005-03-23 2006-09-28 Abbott Laboratories Delivery of highly lipophilic agents via medical devices
EP1909973B1 (en) * 2005-07-15 2018-08-22 Micell Technologies, Inc. Polymer coatings containing drug powder of controlled morphology
US20090062909A1 (en) 2005-07-15 2009-03-05 Micell Technologies, Inc. Stent with polymer coating containing amorphous rapamycin
KR101492545B1 (ko) * 2005-07-15 2015-02-12 미셀 테크놀로지즈, 인코포레이티드 제어된 형태의 약물 분말을 함유하는 중합체 코팅
RU2423381C2 (ru) 2005-07-25 2011-07-10 Трабьон Фармасьютикалз, Инк. Снижение количества в-клеток с использованием cd37-специфических и cd20-специфических связывающих молекул
US20070026042A1 (en) * 2005-07-29 2007-02-01 Narayanan Pallasssana V System for treating aneurysmal disease
US20070048350A1 (en) * 2005-08-31 2007-03-01 Robert Falotico Antithrombotic coating for drug eluting medical devices
WO2007037544A1 (ja) * 2005-09-30 2007-04-05 Kyoto University 制御性ｔ細胞の製造を向上させる薬剤のスクリーニング方法の開発、及び免疫抑制性のマクロライド系抗生剤を用いる制御性ｔ細胞の製造方法
US8784860B2 (en) * 2005-10-27 2014-07-22 Cordis Corporation Local administration of a combination of rapamycin and cilostazol for the treatment of vascular disease
US20070173787A1 (en) * 2005-11-01 2007-07-26 Huang Mark C T Thin-film nitinol based drug eluting stent
US20070116736A1 (en) * 2005-11-23 2007-05-24 Argentieri Dennis C Local vascular delivery of PI3 kinase inhibitors alone or in combination with sirolimus to prevent restinosis following vascular injury
US20070128242A1 (en) * 2005-12-01 2007-06-07 Zhao Jonathan Z Polymeric compositions for controlled release or delivery of pharmacologically active agents
AU2006322030A1 (en) * 2005-12-07 2007-06-14 Wyeth Methods for preparing crystalline rapamycin and for measuring crystallinity of rapamycin compounds using differential scanning calorimetry
US7700614B2 (en) 2005-12-14 2010-04-20 Abbott Laboratories One pot synthesis of tetrazole derivatives of rapamycin
US7842312B2 (en) * 2005-12-29 2010-11-30 Cordis Corporation Polymeric compositions comprising therapeutic agents in crystalline phases, and methods of forming the same
US7678901B2 (en) 2006-02-28 2010-03-16 Wyeth Rapamycin analogs containing an antioxidant moiety
US20070203169A1 (en) * 2006-02-28 2007-08-30 Zhao Jonathon Z Isomers and 42-epimers of rapamycin ester analogs, methods of making and using the same
US7622477B2 (en) * 2006-02-28 2009-11-24 Cordis Corporation Isomers and 42-epimers of rapamycin alkyl ether analogs, methods of making and using the same
EP2019657B1 (en) 2006-04-26 2015-05-27 Micell Technologies, Inc. Coatings containing multiple drugs
GB0609962D0 (en) * 2006-05-19 2006-06-28 Biotica Tech Ltd Novel compounds
GB0609963D0 (en) * 2006-05-19 2006-06-28 Biotica Tech Ltd Novel compounds
AU2007315790A1 (en) * 2006-06-30 2008-05-08 Interface Biologics, Inc. Bioresponsive polymers
US8506984B2 (en) 2006-07-26 2013-08-13 Cordis Corporation Therapeutic agent elution control process
RU2010104916A (ru) * 2006-08-16 2011-08-20 Михаил В. Благосклонный (US) Способ профилактики и лечения возрастных заболеваний
US10695327B2 (en) 2006-09-13 2020-06-30 Elixir Medical Corporation Macrocyclic lactone compounds and methods for their use
US8088789B2 (en) 2006-09-13 2012-01-03 Elixir Medical Corporation Macrocyclic lactone compounds and methods for their use
US7867988B2 (en) 2006-09-13 2011-01-11 Elixir Medical Corporation Macrocyclic lactone compounds and methods for their use
US8636767B2 (en) 2006-10-02 2014-01-28 Micell Technologies, Inc. Surgical sutures having increased strength
US8067055B2 (en) 2006-10-20 2011-11-29 Biosensors International Group, Ltd. Drug-delivery endovascular stent and method of use
US20080097591A1 (en) 2006-10-20 2008-04-24 Biosensors International Group Drug-delivery endovascular stent and method of use
CA2667228C (en) 2006-10-23 2015-07-14 Micell Technologies, Inc. Holder for electrically charging a substrate during coating
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8414909B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
EP1938800A1 (en) 2006-12-06 2008-07-02 Ranbaxy Laboratories Limited Sirolimus nanodispersion
US11426494B2 (en) 2007-01-08 2022-08-30 MT Acquisition Holdings LLC Stents having biodegradable layers
JP5603598B2 (ja) 2007-01-08 2014-10-08 ミセル テクノロジーズ、インコーポレイテッド 生物分解層を有するステント
EP1952807A1 (en) * 2007-01-24 2008-08-06 LEK Pharmaceuticals D.D. Sirolimus formulation
US20090281059A1 (en) 2007-02-21 2009-11-12 Robert Falotico Coating for a medical device having an anti-thrombotic conjugate
US20080241215A1 (en) 2007-03-28 2008-10-02 Robert Falotico Local vascular delivery of probucol alone or in combination with sirolimus to treat restenosis, vulnerable plaque, aaa and stroke
TW200845960A (en) * 2007-04-05 2008-12-01 Wyeth Corp Wortmannin-rapalog conjugate and uses thereof
CN101815540B (zh) 2007-05-25 2015-08-19 米歇尔技术公司 用于医疗器材涂层的聚合物膜
US20090068266A1 (en) * 2007-09-11 2009-03-12 Raheja Praveen Sirolimus having specific particle size and pharmaceutical compositions thereof
US20090130210A1 (en) * 2007-09-11 2009-05-21 Raheja Praveen Pharmaceutical compositions of sirolimus
US20090074831A1 (en) * 2007-09-18 2009-03-19 Robert Falotico LOCAL VASCULAR DELIVERY OF mTOR INHIBITORS IN COMBINATION WITH PEROXISOME PROLIFERATORS-ACTIVATED RECEPTOR STIMULATORS
KR100930167B1 (ko) * 2007-09-19 2009-12-07 삼성전기주식회사 초광각 광학계
US20110091508A1 (en) 2007-10-05 2011-04-21 Interface Biologics ,Inc. Oligofluorinated cross-linked polymers and uses thereof
JP5907658B2 (ja) 2007-10-19 2016-04-26 インターフェース バイオロジクス，インコーポレーテッド 自己消失性コーティング
US8790684B2 (en) * 2007-10-31 2014-07-29 Cordis Corporation Vascular closure device
US9603980B2 (en) 2008-02-26 2017-03-28 CARDINAL HEALTH SWITZERLAND 515 GmbH Layer-by-layer stereocomplexed polymers as drug depot carriers or coatings in medical devices
US8409601B2 (en) * 2008-03-31 2013-04-02 Cordis Corporation Rapamycin coated expandable devices
US8420110B2 (en) 2008-03-31 2013-04-16 Cordis Corporation Drug coated expandable devices
EP2365003A1 (en) 2008-04-11 2011-09-14 Emergent Product Development Seattle, LLC CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
SG192523A1 (en) 2008-04-17 2013-08-30 Micell Technologies Inc Stents having bioabsorbable layers
US8273404B2 (en) * 2008-05-19 2012-09-25 Cordis Corporation Extraction of solvents from drug containing polymer reservoirs
SI2299821T1 (sl) 2008-06-10 2016-03-31 Abbvie Inc. Triciklične spojine
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
EP2313122B1 (en) 2008-07-17 2019-03-06 Micell Technologies, Inc. Drug delivery medical device
WO2010024898A2 (en) 2008-08-29 2010-03-04 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
EP2352459A4 (en) * 2008-10-03 2013-09-25 Elixir Medical Corp MACROCYCLIC LACTONE COMPOUNDS AND METHODS OF USE
US20100098770A1 (en) * 2008-10-16 2010-04-22 Manikandan Ramalingam Sirolimus pharmaceutical formulations
EP2365802B1 (en) 2008-11-11 2017-08-02 The Board of Regents,The University of Texas System Microcapsules of rapamycin and use for treating cancer
EP2671888A1 (en) * 2008-12-23 2013-12-11 Gilead Pharmasset LLC 3',5'-cyclic nucleoside phosphate analogues
CL2009002208A1 (es) * 2008-12-23 2010-10-29 Gilead Pharmasset Llc Un compuesto (2s)-2-((((2r,3r,4r,5r)-5-(2-amino-6-etoxi-9h-purin-9-il)-4-fluoro-3-hidroxi-4-metiltetrahidrofuran-2-il)metoxi)(hidroxi)fosforilamino)propanoico, inhibidores de la replicacion de arn viral; composicion farmaceutica; y su uso en el tratamiento de infeccion por hepatitis c, virus del nilo occidental, entre otras.
EA019341B1 (ru) 2008-12-23 2014-02-28 Джилид Фармассет, Ллс. Фосфорамидаты нуклеозидов
US8834913B2 (en) 2008-12-26 2014-09-16 Battelle Memorial Institute Medical implants and methods of making medical implants
EP2391401A2 (en) * 2009-02-02 2011-12-07 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Crystalline drug-containing coatings
US20100233733A1 (en) * 2009-02-10 2010-09-16 Nodality, Inc., A Delaware Corporation Multiple mechanisms for modulation of the pi3 kinase pathway
FR2943539B1 (fr) 2009-03-31 2011-07-22 Ethypharm Sa Composition pharmaceutique comprenant un macrolide immunosuppresseur de la famille des limus.
US9981072B2 (en) 2009-04-01 2018-05-29 Micell Technologies, Inc. Coated stents
EP2416792A4 (en) 2009-04-10 2012-10-24 Haiyan Qi NEW ANTI-AGING APPROACHES AND METHOD FOR IDENTIFYING THEM
US20100268187A1 (en) * 2009-04-17 2010-10-21 Ranbaxy Laboratories Limited Packaging for sirolimus and composition thereof
CA2759015C (en) 2009-04-17 2017-06-20 James B. Mcclain Stents having controlled elution
US20100280600A1 (en) * 2009-04-30 2010-11-04 Vipul Bhupendra Dave Dual drug stent
US9327060B2 (en) * 2009-07-09 2016-05-03 CARDINAL HEALTH SWITZERLAND 515 GmbH Rapamycin reservoir eluting stent
US20110137407A1 (en) 2009-07-09 2011-06-09 Thai Minh Nguyen Bare metal stent with drug eluting reservoirs
EP2453834A4 (en) 2009-07-16 2014-04-16 Micell Technologies Inc MEDICAL DEVICE DISPENSING MEDICINE
EP2762142A1 (en) 2009-10-30 2014-08-06 ARIAD Pharmaceuticals, Inc. Compositions for treating cancer
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
EP3950692A1 (en) 2009-12-01 2022-02-09 AbbVie Inc. Novel tricyclic compounds
EP2506713A4 (en) * 2009-12-01 2014-09-03 Abbvie Inc NEW TRICYCLIC COMPOUNDS
US8951595B2 (en) 2009-12-11 2015-02-10 Abbott Cardiovascular Systems Inc. Coatings with tunable molecular architecture for drug-coated balloon
US8480620B2 (en) 2009-12-11 2013-07-09 Abbott Cardiovascular Systems Inc. Coatings with tunable solubility profile for drug-coated balloon
US11369498B2 (en) 2010-02-02 2022-06-28 MT Acquisition Holdings LLC Stent and stent delivery system with improved deliverability
WO2011128910A2 (en) 2010-03-02 2011-10-20 Rpg Life Sciences Limited A drug delivery solid dosage formulation of sirolimus
US8795762B2 (en) 2010-03-26 2014-08-05 Battelle Memorial Institute System and method for enhanced electrostatic deposition and surface coatings
WO2011123668A2 (en) 2010-03-31 2011-10-06 Pharmasset, Inc. Stereoselective synthesis of phosphorus containing actives
WO2011133655A1 (en) 2010-04-22 2011-10-27 Micell Technologies, Inc. Stents and other devices having extracellular matrix coating
EP2593039B1 (en) 2010-07-16 2022-11-30 Micell Technologies, Inc. Drug delivery medical device
US20120130481A1 (en) 2010-11-18 2012-05-24 Robert Falotico Local vascular delivery of adenosine a2a receptor agonists in combination with other agents to reduce myocardial injury
US20120303115A1 (en) 2011-05-25 2012-11-29 Dadino Ronald C Expandable devices coated with a rapamycin composition
US20120302954A1 (en) 2011-05-25 2012-11-29 Zhao Jonathon Z Expandable devices coated with a paclitaxel composition
US10464100B2 (en) 2011-05-31 2019-11-05 Micell Technologies, Inc. System and process for formation of a time-released, drug-eluting transferable coating
EP2532740A1 (en) 2011-06-11 2012-12-12 Michael Schmück Antigen-specific CD4+ and CD8+ central-memory T cell preparations for adoptive T cell therapy
US10117972B2 (en) 2011-07-15 2018-11-06 Micell Technologies, Inc. Drug delivery medical device
US10188772B2 (en) 2011-10-18 2019-01-29 Micell Technologies, Inc. Drug delivery medical device
CN102372726B (zh) * 2011-11-08 2014-02-19 福建省微生物研究所 西罗莫司粗晶的制备方法
CN102433364B (zh) * 2011-11-10 2013-10-23 中科医药行业生产力促进中心有限公司 一种微生物发酵法制取雷帕霉素的工艺
EP2594260A1 (en) 2011-11-18 2013-05-22 LEK Pharmaceuticals d.d. Solid preparations comprising sirolimus with desired bioavailability and method for its preparation
AU2012351728A1 (en) 2011-12-16 2014-06-19 Oncology Institute Of Southern Switzerland Combination of inotuzumab ozogamicin and torisel for the treatment of cancer
GB201122305D0 (en) 2011-12-23 2012-02-01 Biotica Tech Ltd Novel compound
US9365880B2 (en) 2012-04-12 2016-06-14 Natco Pharma Limited Fermentation process for the production of rapamycin
CN104203959B (zh) 2012-06-08 2017-09-15 百多力股份公司 雷帕霉素40‑o‑环状烃酯、组合物和方法
US9278090B2 (en) 2012-09-05 2016-03-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of preventing the development of mucositis and related disorders
EP2914260A1 (en) 2012-10-31 2015-09-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preventing antiphospholipid syndrome (aps)
WO2014072984A1 (en) 2012-11-06 2014-05-15 Natco Pharma Limited Improved process for isolation and purification of rapamycin from fermentation broth
WO2014078522A1 (en) 2012-11-14 2014-05-22 Ohio State Innovation Foundation Materials and methods useful for treating glioblastoma
CN105307597A (zh) 2013-03-12 2016-02-03 脉胜医疗技术公司 可生物吸收的生物医学植入物
EP2968281B1 (en) 2013-03-13 2020-08-05 The Board of Regents of The University of Texas System Mtor inhibitors for prevention of intestinal polyp growth
CN105377318A (zh) 2013-05-15 2016-03-02 脉胜医疗技术公司 可生物吸收的生物医学植入物
CN113768881A (zh) 2013-10-08 2021-12-10 人工智能治疗公司 用于治疗淋巴管平滑肌瘤病的雷帕霉素
BR112016010716A8 (pt) 2013-11-13 2020-04-22 Novartis Ag dose de reforço imunológico, baixa, de um inibidor de mtor, seu uso, e adjuvante de vacina
CN106459989B (zh) 2013-12-19 2023-02-17 诺华股份有限公司 人间皮素嵌合抗原受体及其用途
EP3087101B1 (en) 2013-12-20 2024-06-05 Novartis AG Regulatable chimeric antigen receptor
AU2014373683B2 (en) 2013-12-31 2020-05-07 Rapamycin Holdings, Llc Oral rapamycin nanoparticle preparations and use
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
US10307371B2 (en) 2014-02-11 2019-06-04 AI Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
JP2017505789A (ja) 2014-02-11 2017-02-23 ラム・セラピューティクス，インコーポレーテッド リンパ脈管筋腫症の治療のためのラパマイシン
US20170081411A1 (en) 2014-03-15 2017-03-23 Novartis Ag Regulatable chimeric antigen receptor
EP3119423B1 (en) 2014-03-15 2022-12-14 Novartis AG Treatment of cancer using chimeric antigen receptor
CA2944075C (en) 2014-04-04 2022-06-28 Lam Therapeutics, Inc. An inhalable rapamycin formulation for treating age-related conditions
EP3888674B1 (en) 2014-04-07 2024-04-03 Novartis AG Treatment of cancer using anti-cd19 chimeric antigen receptor
WO2016014553A1 (en) 2014-07-21 2016-01-28 Novartis Ag Sortase synthesized chimeric antigen receptors
CA2955386A1 (en) 2014-07-21 2016-01-28 Novartis Ag Treatment of cancer using humanized anti-bcma chimeric antigen receptor
JP6831777B2 (ja) 2014-07-21 2021-02-17 ノバルティス アーゲー Ｃｄ３３キメラ抗原受容体を使用する癌の処置
EP3193915A1 (en) 2014-07-21 2017-07-26 Novartis AG Combinations of low, immune enhancing. doses of mtor inhibitors and cars
WO2016019300A1 (en) 2014-07-31 2016-02-04 Novartis Ag Subset-optimized chimeric antigen receptor-containing t-cells
US10851149B2 (en) 2014-08-14 2020-12-01 The Trustees Of The University Of Pennsylvania Treatment of cancer using GFR α-4 chimeric antigen receptor
CN107108744B (zh) 2014-08-19 2020-09-25 诺华股份有限公司 抗cd123嵌合抗原受体(car)用于癌症治疗
EP3193902A4 (en) 2014-09-11 2018-03-28 The Regents of The University of California mTORC1 INHIBITORS
DK3194443T3 (da) 2014-09-17 2021-09-27 Novartis Ag Målretning af cytotoksiske celler med kimære receptorer i forbindelse med adoptiv immunterapi
EP3209330B1 (en) 2014-10-07 2022-02-23 AI Therapeutics, Inc. An inhalable sirolimus formulation for the treatment of pulmonary hypertension
JP6815992B2 (ja) 2014-10-08 2021-01-20 ノバルティス アーゲー キメラ抗原受容体療法に対する治療応答性を予測するバイオマーカーおよびその使用
EP3473253A1 (en) 2014-10-29 2019-04-24 University Of Maryland Methods of treating age-related symptoms in mammals and compositions therefor
MA40910A (fr) 2014-11-07 2017-09-12 Civitas Therapeutics Inc Poudres de rapamycine pour administration pulmonaire
WO2016098078A2 (en) 2014-12-19 2016-06-23 Novartis Ag Dimerization switches and uses thereof
WO2016130645A1 (en) 2015-02-10 2016-08-18 Lam Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
US20180140602A1 (en) 2015-04-07 2018-05-24 Novartis Ag Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
CN104844620B (zh) * 2015-04-10 2018-06-19 鲁南新时代生物技术有限公司 一种雷帕霉素的分离纯化方法
ES2948133T3 (es) 2015-04-17 2023-08-31 Novartis Ag Métodos para mejorar la eficacia y expansión de células que expresan un receptor de antígeno quimérico
WO2016172583A1 (en) 2015-04-23 2016-10-27 Novartis Ag Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
EP3297629A1 (en) 2015-05-20 2018-03-28 Novartis AG Pharmaceutical combination of everolimus with dactolisib
WO2017029391A1 (en) 2015-08-20 2017-02-23 INSERM (Institut National de la Santé et de la Recherche Médicale) New method for treating cancer
EP3341381A4 (en) * 2015-08-28 2019-06-12 Buck Institute for Research on Aging RAPAMYCIN ANALOGUE WITH IMPROVED MTORC1 SPECIFICITY
CN116270646A (zh) 2015-10-16 2023-06-23 艾伯维公司 制备咪唑并[1,2-a]吡咯并[2,3-e]吡嗪类化合物及其固态形式的方法
US11524964B2 (en) 2015-10-16 2022-12-13 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11773106B2 (en) 2015-10-16 2023-10-03 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11512092B2 (en) 2015-10-16 2022-11-29 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
EP3373927A1 (en) 2015-11-11 2018-09-19 Novartis AG Uses of myostatin antagonists, combinations containing them and uses thereof
WO2018017708A1 (en) 2016-07-20 2018-01-25 University Of Utah Research Foundation Cd229 car t cells and methods of use thereof
TWI797091B (zh) 2016-10-07 2023-04-01 瑞士商諾華公司 利用嵌合抗原受體之癌症治療
CA3044355A1 (en) 2016-11-23 2018-05-31 Novartis Ag Methods of enhancing immune response with everolimus, dactolisib or both
SG11201908226XA (en) 2017-02-10 2019-10-30 Mount Tam Therapeutics Inc Rapamycin analog
WO2018201056A1 (en) 2017-04-28 2018-11-01 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
US20200129486A1 (en) 2017-06-26 2020-04-30 Inserm (Institut National De La Santé Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of olmsted syndrome
AR112834A1 (es) 2017-09-26 2019-12-18 Novartis Ag Derivados de rapamicina
US10596165B2 (en) 2018-02-12 2020-03-24 resTORbio, Inc. Combination therapies
EP3784351A1 (en) 2018-04-27 2021-03-03 Novartis AG Car t cell therapies with enhanced efficacy
US20210396739A1 (en) 2018-05-01 2021-12-23 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
AU2019262978B2 (en) 2018-05-01 2023-07-13 Revolution Medicines, Inc. C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors
IL312291A (en) 2018-05-01 2024-06-01 Revolution Medicines Inc C-26-linked rapamycin analogs as MTOR inhibitors
MX2020013443A (es) 2018-06-13 2021-02-26 Novartis Ag Receptores de antigeno quimerico de bcma y usos de los mismos.
EP3826649A4 (en) 2018-07-23 2022-07-20 Enclear Therapies, Inc. METHODS OF TREATMENT OF NEUROLOGICAL DISORDERS
AU2019310040A1 (en) 2018-07-23 2021-02-11 Enclear Therapies, Inc. Methods of treating neurological disorders
WO2020053125A1 (en) 2018-09-10 2020-03-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of neurofibromatosis
KR20210105397A (ko) 2018-12-18 2021-08-26 노파르티스 아게 라파마이신 유도체
JP7461369B2 (ja) 2019-03-26 2024-04-03 ノバルティス アーゲー イソチアゾリジン１，１－ジオキシド及び１，４－ブタンスルトン含有ラパマイシン誘導体並びにその使用
KR20220011123A (ko) 2019-04-11 2022-01-27 엔클리어 테라피스, 인크. 뇌척수액 개선 방법 및 이를 위한 디바이스 및 시스템
US20220409567A1 (en) * 2021-06-23 2022-12-29 Thomas Winston Adjuvant and complementary therapies for the treatment of cancer
US20240082249A1 (en) 2022-05-25 2024-03-14 Revolution Medicines, Inc. Methods of treating cancer with an mtor inhibitor
WO2024008799A1 (en) 2022-07-06 2024-01-11 Institut National de la Santé et de la Recherche Médicale Methods for the treatment of proliferative glomerulonephritis
WO2024028433A1 (en) 2022-08-04 2024-02-08 Institut National de la Santé et de la Recherche Médicale Methods for the treatment of lymphoproliferative disorders
US20240360153A1 (en) 2023-04-07 2024-10-31 Regeneron Pharmaceuticals, Inc. Selective rapamycin analogs and uses thereof

Also Published As

Publication number Publication date
GB1436447A (en) 1976-05-19
CH591558A5 (nl) 1977-09-30
DE2347682A1 (de) 1974-04-11
YU37358B (en) 1984-08-31
DD107070A5 (nl) 1974-07-12
NL175641C (nl) 1984-12-03
IN139114B (nl) 1976-05-08
FR2201076B1 (nl) 1977-09-09
CS185630B2 (en) 1978-10-31
AR197832A1 (es) 1974-05-10
NL175641B (nl) 1984-07-02
HU166346B (nl) 1975-03-28
DK134607B (da) 1976-12-06
US3929992A (en) 1975-12-30
SE399437B (sv) 1978-02-13
AU6044773A (en) 1975-03-20
YU246473A (en) 1983-04-27
NL7313386A (nl) 1974-04-02
IE38267L (en) 1974-03-29
HK51079A (en) 1979-08-03
IE38267B1 (en) 1978-02-01
FR2201076A1 (nl) 1974-04-26
DE2347682C2 (de) 1984-08-02
DK134607C (nl) 1977-05-16
ZA737247B (en) 1975-04-30
AU474405B2 (en) 1976-07-22
ES419160A1 (es) 1976-06-16
BE805505A (fr) 1974-03-28

Similar Documents

Publication Publication Date Title
CA1000631A (en) Rapamycin from streptomyces hygroscopicus nrrl 5491
AU513641B2 (en) Antibiotics from streptomyces overmitilis
IE43874L (en) Cephalosporin derivatives.
CA984321A (en) Amphoteric antibiotic at-125 from streptomyces
CA992535A (en) Antibiotic derivatives
CA995609A (en) Phleomycin group antibiotics from streptomyces
AU1430376A (en) Antibiotic
AU1201476A (en) Sreptomycetal antibiotic
NZ180898A (en) Antibiotic lysolipin from streptomyces violaceoniger strain nrrl 8097
CA919607A (en) Antibiotic compounds from streptomyces mycarofaciens
IE43965L (en) Cephalosporin derivatives.
CA1028263A (en) Cephalosporin type antibiotic from streptomyces chartreusis
CA1034524A (en) Antibiotic u-43,795 from streptomyces sviceus
AU513827B2 (en) Streptomyces candidys antibiotics
CA986862A (en) Cephalosporin-type antibiotic from streptomyces
CA1032100A (en) Antibiotics xk-88 series from streptomyces hofuensis
CA975316A (en) Salinomycin from streptomyces albus
CA975315A (en) Antibiotic sf 1293 from streptomyces hygroscopicus
CA926329A (en) Antibiotic negamycin from streptomyces purpeofuscus
CA1030885A (en) 7-methoxycephalosporin from streptomyces
NZ184262A (en) Antibiotic bl580 from streptomyces hygroscopicus nrrl 8180
AU536203B2 (en) Antibiotic from streptomyces
IE44352L (en) Cephalosporin derivatives.
AU1175876A (en) Antibiotic
CA989340A (en) Antibiotic no. 5879 (ws-4545) from streptomyces aizunenis